Gadolinium DTPA clinical trials
How each study uses Gadolinium DTPA is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 2 Jun 1988 · MAGNEVIST · NDA 019596 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2003 (4)
| Year | Studies |
|---|---|
| 2003 | 4 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Gadolinium DTPA is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Multihance at 3 Tesla (3T) in Brain TumorsCompletedPhase 4Bracco Diagnostics, IncNCT00395863Written as Arm 2 - MagnevistHow we know
- Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal ArteriesCompletedPhase 3BayerNCT00310557Written as Gadopentetate dimeglumine (Magnevist)How we know
- Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal ArteriesCompletedPhase 3BayerNCT00309075Written as Gadopentetate dimeglumine (Magnevist)How we know
- Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral BranchesCompletedPhase 3BayerNCT00310609Written as Gadopentetate dimeglumine (Magnevist)How we know
- Depiction of Delayed Enhancement in Patients With Documented Myocardial InfarctionCompletedPhase 2BayerNCT00310544Written as Magnevist (Gadopentetate dimeglumine, BAY86-4882)How we know
- Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain MetastasisCompletedPhase 3BayerNCT00681551Written as Magnevist (SH L 451A)How we know
- Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance AngiographyCompletedPhase 2BayerNCT00652418Written as Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)How we know
- Multihance Versus Magnevist in Breast MRICompletedPhase 3Bracco Diagnostics, IncNCT00486473Written as MagnevistHow we know
Given beside what is tested · 1 — Gadolinium DTPA is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with Gadolinium DTPA
- Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese PatientsCompletedPhase 3BayerNCT00395460Written as MagnevistHow we know
- Crossover Study With MultiHance vs a Comparator for Peripheral MRACompletedPhase 3Bracco Diagnostics, IncNCT00408083Written as MagnevistHow we know
Codes
What other systems call Gadolinium DTPA · ClinicalTrials.gg INT008714
- MeSH (NLM) D019786Gadolinium DTPAOne source NLM
- UNII (FDA) K2I13DR72LGADOPENTETIC ACIDConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019786 | Gadolinium DTPA | One source NLM |
| UNII (FDA) | K2I13DR72L | GADOPENTETIC ACID | Confirmed FDA, NLM |
Also registered as gadopentetate dimeglumine (UNII RH248G8V27 · RxNorm 25486).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.